BioWorld Asia

May 22, 2002

View Archived Issues

European Parliament Endorses Part Of Biotech Spending Plan

Rational Drug Discovery Approach Looks Promising For Alzheimer's

Genome Express Offers Bacterial Genomics Sequencing Service

Speedel Moves SPP 301 Into Phase II Pilot Studies

Celltech Picks Amgen To Help Advance Osteoporosis Program

HGS Gets Exclusive Development Rights To CAT Cancer Antibody

CeNeS Releases Positive Interim Results Of CNS5161 In Phase II

Enact Acquires Rights To Cytoxic, Prepares To File For Approvals

Other News To Note

Genset Chairman Resigns, Is Succeeded By Vasseur

Australian States Compete In Separate Biotech Initiatives

IDM Receives Approval For Ovarian Cancer Therapy Trial

Ark Delays Initial Public Offering Due To Unfavorable Conditions

LONDON - Ark Therapeutics Group plc postponed its initial public offering on the London Stock Market, blaming "unusually adverse market conditions." (BioWorld International) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 25, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...